Seed Round Open
Built on IP. Positioned for Scale.
Avant Labs is raising a seed round to accelerate platform licensing, expand the IP portfolio, and bring the next generation of bio-actives delivery technology to market.
Investment Thesis
Why Avant Labs. Why Now.
The global nutraceutical and cosmeceutical markets are converging on a single problem: delivery. Consumers demand efficacy. Brands demand differentiation. Regulators demand precision. Avant Labs has built the infrastructure layer that solves all three — two IP-protected delivery platforms, a growing patent portfolio, and a licensing model that scales without manufacturing overhead.
Large & Growing Market
The global nutraceutical delivery market exceeds $50B and is growing at 8%+ CAGR. Thin-film and advanced topical delivery represent the fastest-growing segments, driven by consumer demand for bioavailability and convenience.
Defensible IP Moat
Avant Labs plans to file multiple patent applications covering AbsorbWell’s proprietary film-matrix compositions, co-formulation technologies, and buccal delivery mechanisms. The Issengard platform is already patent-pending, with claims covering its carrier compositions and device configurations. Each platform is independently licensable, with vertical-specific exclusivity options available.
Asset-Light Licensing Model
Avant Labs licenses technology — not products. No manufacturing capex. No retail distribution risk. Revenue scales through royalties and licensing fees as partners bring formulations to market under their own brands.
Validated Market Traction
50,000+ strips sold. Thousands of marketing samples distributed across brand and creator programs. Four active product lines. Real revenue from a platform that has already crossed from R&D into commercial deployment.
Why Avant Labs
Defensible Moat. Dual Revenue. Massive Market.
IP-Protected Platforms
Defensible Moat
Both delivery platforms are protected by a growing patent portfolio covering formulation methods, carrier compositions, and device configurations. Licensing rights are structured for exclusivity by vertical.
Dual Revenue Architecture
Licensing + Direct
Platform licensing to established brands generates recurring royalty revenue. Direct-to-market product lines under Avant Labs brands provide margin-rich revenue alongside the licensing business.
Next-Generation Bio-Actives
$87B+ TAM
The global nutraceutical and cosmeceutical delivery market is underserved by precision absorption technology. Avant Labs platforms are formulated for the compounds that legacy delivery systems cannot effectively stabilize or deliver.
Placeholder metrics — replace with verified data before investor distribution.
Market Opportunity
Two Platforms. Two Massive Markets.
Buccal Delivery
Buccal Thin-Film Platform
$12B+
Addressable thin-film delivery market
11% CAGR
Projected through 2030
Key drivers: Bioavailability demand, pill fatigue, precision dosing trends in nutraceuticals and peptides
Advanced Topical Delivery
Topical Skin-Binding Platform
$8B+
Addressable topical carrier market
9% CAGR
Projected through 2030
Key drivers: Recovery wellness growth, cosmeceutical convergence, sustained-release demand in sports and therapeutic verticals
IP Portfolio
Four Applications. Two Platforms. One Moat.
Avant Labs has filed four patent applications covering the core compositions and device configurations of both delivery platforms. Each application is independently defensible and creates licensing leverage across distinct commercial verticals.
| Filing | Status |
|---|---|
| Buccal Film Matrix Compositions | Pending |
| Buccal Delivery Mechanism & Device | Pending |
| Topical Carrier Compositions | Pending |
| Topical Device Configurations | Pending |
Founding Team
Built by Operators.
One co-founder brings more than 30 years of experience in biopharmaceutical development, entrepreneurship, and commercialization — with a track record of founding and leading multiple ventures to successful exits. At Avant Labs, that expertise drives the scientific strategy, platform development, and IP portfolio behind our proprietary delivery platforms.
The other co-founder brings more than 25 years of experience across enterprise technology, artificial intelligence, biotechnology, and consumer products — including a prior company exit to Pacific Bell. At Avant Labs, that background powers operations, supply-chain strategy, and the commercial execution required to license platforms at scale.
Use of Proceeds
Seed Capital Allocation
40%
IP & Patent Prosecution
Accelerate patent prosecution, file continuation applications, and expand IP coverage into new verticals and international markets.
30%
Platform R&D
Advance formulation science, develop next-generation carrier compositions, and validate new active compound compatibility across both platforms.
20%
Commercial Licensing
Build the licensing pipeline, engage strategic brand partners, and establish exclusivity agreements in high-value verticals.
10%
Operations & Team
Expand the core team with key hires in business development and formulation science to support platform scale.
Deck Request
Request the Investor Deck
Qualified institutional and accredited investors may request the full pitch deck, financial model, and IP summary. All materials are provided under NDA.